First time in humans studies,

Nasal spray 18 healthy volunteers in Bristol-Myers first time in humans study withdrawal not seen when drug discontinued after 16 days92 Nasal spray Bristol-Myers clinical trial in post-Caesarian-section pain no assessment of abuse liability or withdrawal93 Continued... 

The answers to these questions drive the next issue—of when to switch vendors. The needs of the project may drive the sponsor to run one or more parallel programs with other vendors one campaign to produce materials for first time in human studies, another to produce phase II clinical trail supplies materials, and a third to determine the impact of the different campaigns on the clinical program. Now what started as one sponsor-vendor relationship for one project has turned into three. Multiply this by the number of projects your company is managing at any given time and you will begin to understand the extent of the impact of such a decision. 

Thus, in a first-time-in-human study where sample sizes may be between 12 and 24, and the objective is to characterize the pharmacokinetics of a new molecular entity, using any of the approaches investigated here would suffice. However, the CMI approach is preferred because it accounts for the uncertainty associated with the imputation of the BQL values while the FCSI approach does not. 

Designs for First-Time-in-Human Studies in Nononcology Indications... 

DESIGNS FOR FIRST-TIME-IN-HUMAN STUDIES IN NONONCOLOGY INDICATIONS... 

C. Buoen, O. J. Bjerrum, and M. S. Thomsen, How first-time-in-human studies are performed a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 45 1123-1136 (2005). 

While the efficacy of an approved drug is extremely relevant, so too is its safety profile, sometimes referred to as its toxicity profile since every drug will have some unwanted side effects. Initial safety evaluations are conducted in healthy adult subjects in first time in human (FTTH) studies. The terms healthy volunteers or normal volunteers are often seen in this context, but they seem particularly unsuitable By definition, all participants in all clinical trials are volunteers, and the use of the word volunteer in just Fl IH trials could mistakenly be seen to imply that participants in other trials are not volunteers. Additionally, the word normal seems questionable in that it may mistakenly be seen to imply that subjects in other trials are abnormal in ways not related to having or not having the disease or condition of interest. The term healthy adult subjects circumvents such misperceptions. 

Regulatory toxicology studies performed before drug is administered to humans for the first time in FTIH studies. 

The term should be considered allows flexibility either to do the studies before first time in humans or at a later stage of development. In practice, these studies are most often available before IND, because one wants to cope with this issue in time and wants to provide best safety to volunteers and patients. 

Finally, how informed could a subject be about a new chemical entity when the aim of the study is to gain information for the first time in humans To balance the apparent lack of information, the investigator is responsible for carefully monitoring the subject during all stages of the investigation. 

Clinical development continues with the application of the learn-confirm-learn paradigm applied to drug development. Scale up to the first-time-in-human (FTIH) study is best done by the application of sound PM methods as described by several authors (10, 51, 56). 

The primary objective of first-time-in-human (first-time-in-man or first-in-human) studies is the identification of a suitable dose or dose range for further study, based on the safety and toierabiiity of the substance. These are volunteer subject-based dose-escalation studies that are traditionally small and time-lagged. These studies offer the first opportunity to learn about the drug in humans and serve as a bridge from animal to human. They provide opportunity for confirming the prediction of pharmacokinetics from animals and to learn about the safety of the drug, if the study is appropriately designed. 

The literature is replete with scientific study designs for Phase 1 cancer trials in patients (e.g., see Ref. 10), but such is not the case for first-time-in-human (FTIH)... 

Y. Yin and C. Chen, Optimizing first-time-in-human trial design for studying dose proportionality. Drug Inf J 35 1065-1018 (2001). 

Phase 1 clinical trials, and particularly first-time-in-human (FTIFl) trials are small, uncontrolled, sequential learning studies designed to ... 

---